183 related articles for article (PubMed ID: 37744275)
21. Chlorogenic acid inhibits esophageal squamous cell carcinoma growth in vitro and in vivo by downregulating the expression of BMI1 and SOX2.
Zhan Y; Li R; Feng C; Li X; Huang S; Wang L; Liu Z; Jiang J; Han Y
Biomed Pharmacother; 2020 Jan; 121():109602. PubMed ID: 31707349
[TBL] [Abstract][Full Text] [Related]
22. Effects and mechanisms of FBXO31 on Taxol chemoresistance in esophageal squamous cell carcinoma.
Lv L; Wang SC; Mo JY; Huang KL; Xu ML; Liu J
Biochem Biophys Res Commun; 2022 Jan; 586():129-136. PubMed ID: 34839191
[TBL] [Abstract][Full Text] [Related]
23. SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway.
Gen Y; Yasui K; Nishikawa T; Yoshikawa T
Cancer Sci; 2013 Jul; 104(7):810-6. PubMed ID: 23510069
[TBL] [Abstract][Full Text] [Related]
24. PRMT1 regulates the tumour-initiating properties of esophageal squamous cell carcinoma through histone H4 arginine methylation coupled with transcriptional activation.
Zhao Y; Lu Q; Li C; Wang X; Jiang L; Huang L; Wang C; Chen H
Cell Death Dis; 2019 May; 10(5):359. PubMed ID: 31043582
[TBL] [Abstract][Full Text] [Related]
25. Hsa_circ_0007142 contributes to cisplatin resistance in esophageal squamous cell carcinoma via miR-494-3p/LASP1 axis.
Chang N; Ge N; Zhao Y; Yang L; Qin W; Cui Y
J Clin Lab Anal; 2022 May; 36(5):e24304. PubMed ID: 35312115
[TBL] [Abstract][Full Text] [Related]
26. Reticulocalbin3: A Ca
Cai R; Wang P; Zhao X; Lu X; Deng R; Wang X; Hong C; Lin J
Cancer Sci; 2022 Oct; 113(10):3593-3607. PubMed ID: 35839283
[TBL] [Abstract][Full Text] [Related]
27. SOX2 antagonizes WWC1 to drive YAP1 activation in esophageal squamous cell carcinoma.
Chai Y; Li Q; Zhao H; Zhang Z; Yu X; Pang L; Liu Z; Zhao J; Wang L; Li F
Cancer Med; 2019 Nov; 8(16):7055-7064. PubMed ID: 31560173
[TBL] [Abstract][Full Text] [Related]
28. RAC1 inhibition reverses cisplatin resistance in esophageal squamous cell carcinoma and induces downregulation of glycolytic enzymes.
Zeng RJ; Zheng CW; Gu JE; Zhang HX; Xie L; Xu LY; Li EM
Mol Oncol; 2019 Sep; 13(9):2010-2030. PubMed ID: 31314174
[TBL] [Abstract][Full Text] [Related]
29. ZFX promotes tumorigenesis and confers chemotherapy resistance in esophageal squamous cell carcinoma.
Wu J; Zhou Y; Wang T; Jiang C; Gao Y; Wei B
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101586. PubMed ID: 33662636
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-338-5p reverses chemoresistance and inhibits invasion of esophageal squamous cell carcinoma cells by targeting Id-1.
Han L; Cui D; Li B; Xu WW; Lam AKY; Chan KT; Zhu Y; Lee NPY; Law SYK; Guan XY; Qin YR; Chan KW; Ma S; Tsao SW; Cheung ALM
Cancer Sci; 2019 Dec; 110(12):3677-3688. PubMed ID: 31646712
[TBL] [Abstract][Full Text] [Related]
31. Tumor-associated macrophage (TAM)-secreted CCL22 confers cisplatin resistance of esophageal squamous cell carcinoma (ESCC) cells via regulating the activity of diacylglycerol kinase α (DGKα)/NOX4 axis.
Chen J; Zhao D; Zhang L; Zhang J; Xiao Y; Wu Q; Wang Y; Zhan Q
Drug Resist Updat; 2024 Mar; 73():101055. PubMed ID: 38387281
[TBL] [Abstract][Full Text] [Related]
32. Reciprocal regulation of LINC00941 and SOX2 promotes progression of esophageal squamous cell carcinoma.
Lu JT; Yan ZY; Xu TX; Zhao F; Liu L; Li F; Guo W
Cell Death Dis; 2023 Jan; 14(1):72. PubMed ID: 36717549
[TBL] [Abstract][Full Text] [Related]
33. M2 tumor-associated macrophage mediates the maintenance of stemness to promote cisplatin resistance by secreting TGF-β1 in esophageal squamous cell carcinoma.
Yang K; Xie Y; Xue L; Li F; Luo C; Liang W; Zhang H; Li Y; Ren Y; Zhao M; Wang W; Liu J; Shen X; Zhou W; Fei J; Chen W; Gu W; Wang L; Li F; Hu J
J Transl Med; 2023 Jan; 21(1):26. PubMed ID: 36641471
[TBL] [Abstract][Full Text] [Related]
34. CCT4 knockdown enhances the sensitivity of cisplatin by inhibiting glycolysis in human esophageal squamous cell carcinomas.
Fang J; Ma Y; Li Y; Li J; Zhang X; Han X; Ma S; Guan F
Mol Carcinog; 2022 Nov; 61(11):1043-1055. PubMed ID: 36102200
[TBL] [Abstract][Full Text] [Related]
35. LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1.
Chang ZW; Jia YX; Zhang WJ; Song LJ; Gao M; Li MJ; Zhao RH; Li J; Zhong YL; Sun QZ; Qin YR
J Exp Clin Cancer Res; 2018 Mar; 37(1):56. PubMed ID: 29530057
[TBL] [Abstract][Full Text] [Related]
36. Knockdown of frizzled-7 inhibits cell growth and metastasis and promotes chemosensitivity of esophageal squamous cell carcinoma cells by inhibiting Wnt signaling.
Liu X; Yan Y; Ma W; Wu S
Biochem Biophys Res Commun; 2017 Aug; 490(3):1112-1118. PubMed ID: 28669726
[TBL] [Abstract][Full Text] [Related]
37. lncRNA MIAT promotes esophageal squamous cell carcinoma progression by regulating miR-1301-3p/INCENP axis and interacting with SOX2.
Zhang C; Xie L; Fu Y; Yang J; Cui Y
J Cell Physiol; 2020 Nov; 235(11):7933-7944. PubMed ID: 31943174
[TBL] [Abstract][Full Text] [Related]
38. Silencing HMGN5 suppresses cell growth and promotes chemosensitivity in esophageal squamous cell carcinoma.
Liu X; Ma W; Yan Y; Wu S
J Biochem Mol Toxicol; 2017 Dec; 31(12):. PubMed ID: 28914995
[TBL] [Abstract][Full Text] [Related]
39. RUNX3 reverses cisplatin resistance in esophageal squamous cell carcinoma via suppression of the protein kinase B pathway.
Li DJ; Shi M; Wang Z
Thorac Cancer; 2016 Sep; 7(5):570-580. PubMed ID: 27766776
[TBL] [Abstract][Full Text] [Related]
40. USP10 promotes migration and cisplatin resistance in esophageal squamous cell carcinoma cells.
Hou S; Zhao T; Deng B; Li C; Li W; Huang H; Hang Q
Med Oncol; 2023 Dec; 41(1):33. PubMed ID: 38150085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
